Dermal Toxicity Testing Market - By Type (Product, Service), Testing Method (In Vivo, In Vitro, In Silico Modeling), Test Type (Skin Irritation, Sensitization, & Corrosion, Phototoxicity), End-use (Healthcare, Cosmetics)– Global Forecast 2023-2032
Published on: 2024-07-20 | No of Pages : 240 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Dermal Toxicity Testing Market - By Type (Product, Service), Testing Method (In Vivo, In Vitro, In Silico Modeling), Test Type (Skin Irritation, Sensitization, & Corrosion, Phototoxicity), End-use (Healthcare, Cosmetics)– Global Forecast 2023-2032
Dermal Toxicity Testing Market Size
Dermal Toxicity Testing Market size was valued at USD 2.1 billion in 2022 and is anticipated to grow at a CAGR of around 8.3% between 2023 and 2032. Dermal toxicity testing is a type of safety assessment conducted to evaluate the potential harmful effects of a substance when it comes into contact with the skin.
The goal of dermal toxicity testing is to determine the adverse effects a substance may have on the skin, including irritation, sensitization, and other forms of damage. As per Allergy and Asthma Network Organization of U.S., currently more than 50 million Americans are suffering from one or other kind of allergy. Such rising number of allergy cases is said to increase the demand for dermal toxicity testing.
Additionally, there is a growing recognition of the ethical concerns associated with the use of animals in testing procedures. Several organizations advocate for the reduction and replacement of animal testing due to concerns about the welfare and treatment of animals. Such aforementioned factors will boost industry growth during forecast period.
Report Attribute | Details |
---|---|
Base Year | 2022 |
Dermal Toxicity Testing Market Size in 2022 | USD 2.1 Billion |
Forecast Period | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR | 8.3% |
2032 Value Projection | USD 4.5 Billion |
Historical Data for | 2018 to 2022 |
No. of Pages | 275 |
Tables, Charts & Figures | 360 |
Segments covered | Type, Testing Method, Test Type, End-use, and Region |
Growth Drivers |
|
Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic initially disrupted the dermal toxicity testing market by causing delays in research and development, shift in funding priorities, and supply chain disruption. Laboratories faced challenges due to closures and restrictions, impacting the procurement of testing materials. The pandemic accelerated the adoption of digital technologies and automation in toxicity testing. Regulatory considerations also evolved. Despite challenges, there was an increased focus on product safety, emphasizing the importance of rigorous toxicity testing, including dermal toxicity, reproductive toxicity testing during the pandemic.
Dermal Toxicity Testing Market Trends
High Throughput Screening (HTS) technologies are increasingly being integrated into dermal toxicity testing. These advanced screening methods enable the rapid assessment of several substances, enhancing the efficiency of identifying potential dermal hazards.
- The use of automated systems and robotics in the testing process contributes to streamlining procedures and significantly increasing throughput. This integration improves the speed and cost-effectiveness of dermal toxicity testing, making it a valuable approach in safety assessment protocols.
- The high-throughput nature of these technologies accelerates the testing process compared to traditional methods. Automated systems and robotics can handle multiple samples concurrently, reducing the time required for dermal toxicity assessment. This is crucial for industries that require quick and reliable safety evaluations during product development.
- Robotic systems are commonly used in HTS for dermal toxicity testing. These systems are equipped with advanced liquid handling capabilities, allowing for accurate and reproducible dispensing of test substances. The use of robotics ensures uniformity in testing conditions and reduces the potential for human errors.
Dermal Toxicity Testing Market Analysis
The market by type is categorized into product and services. Services segment is further bifurcated into inhouse and outsource services. The services segment garnered USD 1.2 billion revenue size in the year 2022.
- The trend of outsourcing dermal toxicity testing to specialized contract research organizations (CROs) is on rise. Companies often choose to collaborate with CROs to access their expertise, specialized equipment, and cost-effective services, allowing them to focus on their core competencies.
- Dermal toxicity testing services are increasingly integrating advanced technologies such as high-throughput screening, automation, and computational modeling. These technologies enhance the efficiency and accuracy of testing, providing clients with more comprehensive and reliable data.
- The cosmetics and personal care industries continue to drive demand for dermal toxicity testing services. Consumers' increasing awareness and concern about the safety of cosmetic products contribute to the need for thorough and reliable testing in this sector.
Moreover, rising awareness, improving healthcare infrastructure, and rising healthcare expenditure further contributes to market expansion.
Based on testing method, the dermal toxicity testing market is segmented into in-vivo testing, in-vitro testing and in-silico modeling. The in-vitro testing segment dominated the market and accounted for over 42% business share in the year 2022.
- Rise in in-vitro toxicology testing adoption due to advancements in cell culture technologies have improved the reliability and relevance of in vitro models.
- The development of more sophisticated 3D cell culture models has been a significant trend. These models better mimic the complexity of human skin, allowing for more accurate predictions of dermal toxicity compared to traditional 2D cell cultures.
Based on test type, the dermal toxicity testing market is segmented into skin irritation, skin sensitization skin corrosion, and phototoxicity tests. The skin sensitization test segment dominated the market and accounted for over 30% business share in the year 2022.
- Shift towards non-animal testing methods due to growing demand for developing non-animal testing methods for skin sensitization assessment. This includes in vitro assays that aim to replace or reduce the reliance on animal testing, aligning with ethical considerations and regulatory preferences for alternative methods.
- In vitro assays for skin sensitization have gained prominence. These tests use human-derived cells to assess sensitization potential, offering a more relevant and human-centric approach compared to traditional animal models.
- Thus, aforementioned factors will promote market expansion during forecast timeframe.
Based on end-use, the dermal toxicity testing market is segmented into varied industries including healthcare, cosmetics and personal care products, chemical industry, and other end-users. The healthcare industry segment accounted for over 31% business share in the year 2022.
- The globalization of clinical trials in the healthcare industry requires standardized and accepted dermal toxicity testing methods across different regions. Companies are seeking consistent testing approaches to meet regulatory requirements worldwide.
- Collaboration and outsourcing of dermal toxicity testing services are observed in the healthcare industry. Pharmaceutical and medical device companies often partner with specialized contract research organizations (CROs) to access expertise and advanced testing capabilities.
U.S. dermal toxicity testing market accounted for over USD 1.9 billion revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.
- The U.S. market has witnessed an increased emphasis on alternatives to traditional animal testing methods. In vitro testing methods, including cell culture and tissue engineering, have gained traction due to ethical considerations and regulatory support for reducing animal use.
- The U.S. regulatory landscape, led by agencies such as the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA), continues to influence trends in dermal toxicity testing. Companies are increasingly focusing on aligning with regulatory requirements and guidelines to ensure market approval.
Moreover, awareness of the environmental impact of certain substances has led to an increased focus on dermal toxicity testing in the context of environmental risk assessments. This trend aligns with broader environmental sustainability considerations. Hence, the above-mentioned factors are said to be some of the key factors driving the market development.
Dermal Toxicity Testing Market Share
The dermal toxicity testing industry is fragmented, with key players including Eurofins Scientific, MatTek Corporation and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, on September 14, 2023, MatTek expanded its culture ware range by introducing Ultra Low Attachment (ULA) Spheroid Plates for advanced spheroid cell culture applications. These plates, offered in collaboration with faCellitate, are sold under the BIOFLOAT brand in both 96-well and 384-well formats, thereby enhancing sales of dermal toxicity testing benefitting the industry players.
Some of the eminent market participants operating in the dermal toxicity testing industry include
- QIMA LTD
- Charles River Laboratories
- Evotec
- MatTek Corporation
- Eurofins Scientific
- SGS Group
- Intertek Group
- InVivo Biosystems
- Eurofins Scientific
- Qiagen N.V.
Dermal Toxicity Testing Industry News
- In January 2023, Eurofins Scientific extended its presence in India with a state-of-the-art laboratory in Genome Valley, Hyderabad, offering comprehensive services to pharmaceutical and biotech companies in various research areas. The lab will provide safety toxicology testing along with other testing which will benefit the company in expanding its geographical footprint.
- In January 2021, Charles River revealed a collaboration with Cypre, Inc., aimed at broadening their services in 3D in-vitro models for cancer immunotherapy and targeted therapy drug screening. This strategic partnership granted Charles River access to Cypre's proprietary 3D hydrogel technology, Falcon-X, facilitating the expansion of their service offerings.
Dermal toxicity testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Type, 2018 – 2032 (USD Million)
- Product
- Services
- Inhouse services
- Outsource services
By Testing Method, 2018 – 2032 (USD Million)
- In-vivo testing
- In-vitro testing
- In-silico modeling
By Test Type, 2018 – 2032 (USD Million)
- Skin irritation tests
- Skin sensitization tests
- Skin corrosion tests
- Phototoxicity tests
By End-use, 2018 – 2032 (USD Million)
- Healthcare industry
- Cosmetics and personal care products industry
- Chemical industry
- Other end-users
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- Malaysia
- Philippines
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa